Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

- PMLiVE

Actavis ‘considering’ white knight bid for Allergan

Wall Street Journal says Irish pharma company set to challenge Valeant's bid

- PMLiVE

Valeant dangles higher bid in front of Allergan shareholders

Proposes $200 a share deal

- PMLiVE

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

Gilead Sciences

Gilead gets EU nod for cancer drug Zydelig

Approved for patients with chronic lymphocytic leukaemia and follicular lymphoma

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

Allergan agrees to shareholder meeting on Valeant bid

Pershing Square Capital convinces shareholders to request consultation

Bristol Myers Squibb logo

BMS and Celgene to research cancer immunotherapy combo

Companies will study combination of nivolumab and Abraxane

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links